GC Cell
107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Yongin-si, Gyeonggi-do, 16924, South Korea
Overview
GC Cell, founded to specialize in cell therapy, obtained approval for its developed Immunecell-LC as a liver cancer immunotherapy agent in 2007. Immunecell-LC has now finished third-phase clinical trials on liver cancer and brain tumors (glioblastoma/GBM), and is tailed by studies, published in SCI-level journals, on its efficacy in treating liver cancer, brain tumors, and pancreatic cancer (researcher-conducted clinical trial). The company is now researching and developing CAR-T, a next-generation cell immunotherapy agent, and, in partnership with ToolGen, a T-cell-based next-generation cancer immunotherapy agent with greater performance.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Life Science
- Therapeutics
Investment portfolio
- Feldan Therapeutics
Participated · Series B · Jun 2023
Feldan Therapeutics is a Canada-based early clinical-stage pharmaceutical company developing treatments that enable intracellular delivery of biomolecules via its proprietary Feldan Shuttle peptide technology. Its lead candidate, FLD-103, is delivered directly into basal cell carcinoma (BCC) lesions to transport a Hedgehog inhibitor to target cells and is in a Phase 1/2a clinical trial. The company is expanding its pipeline into skin and pulmonary programs, leveraging the Shuttle’s ability to reach hard-to-deliver lung cells to address respiratory diseases. Feldan’s platform focuses on safe and efficient delivery of antisense oligonucleotides and other biomolecules to unlock new therapeutic approaches. The article does not disclose operating metrics or financing amounts. Feldan Therapeutics is a Quebec City, Canada–based biopharmaceutical company focused on developing therapies enabled by intracellular delivery. Led by CEO Francois-Thomas Michaud, the company designed the Feldan Shuttle, a proprietary peptide-based technology that delivers compounds inside cells to access intracellular targets. Its pipeline focuses on diseases affecting skin and lungs, including FLD-103, an intralesional candidate for basal cell carcinoma (BCC). The company intends to use the Series B proceeds to conduct clinical Phase I/II studies of FLD-103 and to advance its pulmonary program to the preclinical stage. Feldan completed an initial closing of a $16.5M Series B and has backing from both new and existing investors. Feldan Therapeutics has developed the Feldan Shuttle, a patented peptide-based platform that enables fast, safe and highly efficient intracellular delivery of proteins and peptides both in vivo and ex vivo. The company is advancing a pipeline of therapeutic applications that leverage this intracellular delivery technology. Proceeds from the Series A financing will support preclinical work intended to enable transfer of the technology into clinical trials. Feldan has an existing collaboration with GC focused on the development of NK cell–based therapeutics and describes GC as a strategic, long-term investor. The company is based in Québec City and is led by CEO and co-founder Francois-Thomas Michaud.
Team
No current team members are available.